PTC Therapeutics, Inc. (PTCT)
NASDAQ: PTCT · Real-Time Price · USD
46.24
+0.99 (2.19%)
Dec 20, 2024, 4:00 PM EST - Market closed
PTC Therapeutics Revenue
PTC Therapeutics had revenue of $196.79M in the quarter ending September 30, 2024, with 0.11% growth. This brings the company's revenue in the last twelve months to $900.66M, up 12.84% year-over-year. In the year 2023, PTC Therapeutics had annual revenue of $937.82M with 34.20% growth.
Revenue (ttm)
$900.66M
Revenue Growth
+12.84%
P/S Ratio
3.92
Revenue / Employee
$853,710
Employees
1,055
Market Cap
3.57B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 937.82M | 239.02M | 34.20% |
| Dec 31, 2022 | 698.80M | 160.21M | 29.75% |
| Dec 31, 2021 | 538.59M | 157.83M | 41.45% |
| Dec 31, 2020 | 380.77M | 73.79M | 24.04% |
| Dec 31, 2019 | 306.98M | 42.25M | 15.96% |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
| Dec 31, 2014 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Oscar Health | 8.22B |
| Organon & Co. | 6.41B |
| Perrigo Company | 4.39B |
| DENTSPLY SIRONA | 3.90B |
| Acadia Healthcare Company | 3.12B |
| Sotera Health Company | 1.12B |
| Alvotech | 393.92M |
| CRISPR Therapeutics AG | 202.83M |
PTCT News
- 2 days ago - PTC Therapeutics Announces Vatiquinone NDA Submission to FDA for the Treatment of Children and Adults Living with Friedreich Ataxia - PRNewsWire
- 4 days ago - PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - PRNewsWire
- 19 days ago - PTC Therapeutics Stock Soars on Novartis Licensing Agreement - Investopedia
- 19 days ago - PTC Therapeutics Inks Licensing Pact With Novartis Worth Up To ~$3 Billion For Huntington's Program - Benzinga
- 19 days ago - PTC Therapeutics signs up to $1.9 billion licensing deal with Novartis - Reuters
- 19 days ago - PTC Therapeutics Enters into a Global License and Collaboration Agreement with Novartis for PTC518 Huntington's Disease Program - PRNewsWire
- 24 days ago - PTC Therapeutics Ends Utreloxastat Development After Rare Neurodegenerative Disease Trial Misses Goal, Analyst Maintains Outperform With Focus On Sepiapterin, Huntington's Programs - Benzinga
- 24 days ago - PTC Therapeutics Enters into Agreement to Sell Priority Review Voucher for $150 Million - PRNewsWire